
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab is well-positioned to continue its strong financial performance based on its impressive pipeline of cancer therapeutics and partnerships with major pharmaceutical companies. Its latest financial results showed solid revenue and earnings, and the company has issued positive guidance for 2026. With a strong balance sheet and a track record of profitability, Genmab is well-equipped to weather potential challenges in the biotech sector, making it an attractive stock for investors. However, there are risks to consider, such as the potential for slowing DARZALEX sales and negative outcomes from clinical trials, which could impact the company's financial performance.
Bears say
Genmab is currently highly reliant on their partnership with Johnson & Johnson for their leading product Darzalex, as well as other partnerships for their pipeline candidates. The recent positive top-line results for ELREXFIO, a competitor to Darzalex, may pose a threat to Genmab's market share and could lead to a slowdown in sales. Furthermore, the company faces risks such as potential label extension failures, lower-than-expected product penetration, and possible failures of other agents in clinical testing, which could impact their future financial performance.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares